glp-1 agonist tablets New Pill Foundayo (Orforglipron) Gets FDA Approval for Obesity Wegovy pill: Oral GLP-1 receptor

These symptoms result from the progressive loss of dopamine-producing neurons in the brain

J Am Soc Nephrol 2010;21:527-35.ArticlePubMedPMC 13

Another potential concern some individuals have noted is a change in facial appearance, often called 'Ozempic face.' This isn't caused by the medication itself but rather by the rapid weight loss that can occur

Recently, to ensure the safety of GLP-1 RA on sarcopenia, a clinical randomized multicenter trial of bimagrumab, an antibody blockade of activin type II receptor inhibitor, alone or in addition to subcutaneous semaglutide is now ongoing (NCT05616013) [113]

Clinical Diabetes and Endocrinology